Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Mar 6, 2002

Keywords

ClinConnect Summary

Herpes simplex encephalitis (HSE) remains the most common cause of sporadic fatal encephalitis in the world. This study is a phase III, double-blind, placebo controlled study of long term therapy with valacyclovir as a treatment of herpes encephalitis. The primary objective of this study is to assess the impact of valacyclovir (VACV) therapy (following standard intravenous acyclovir therapy) on neuropsychological impairment at one year post therapy, based on the cumulative scores of the Mattis Dementia Rating Scale (MDRS). The secondary objectives of the study are to: assess the effect of t...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed consent and/or assent must be obtained from the patient or legal guardian.
• • Patients with encephalopathy consistent with herpes simplex encephalitis (HSE) whose cerebral spinal fluid (or brain biopsy sample) is positive for herpes simplex virus (HSV) deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR).
• • Patients who are receiving and will have completed intravenous (IV) acyclovir (ACV) therapy for a minimum duration of 14 days to a maximum of 21 days and a minimum dose of 30 mg/kg/day to a maximum of 60 mg/kg/day, or equivalent dose as adjusted for renal dysfunction.
• • Patient is expected to be available for follow-up visits of study drug administration and through the 24 month study visit.
• • Patients who are 12 years of age or older.
• • Patients who weigh greater than or equal to 45.5kg (100 pounds).
• • All female patients with childbearing potential must have a negative pregnancy test within 72 hours prior to initiation of study drug. If the pregnancy test is positive, the patient is ineligible for the study.
• • Women must be post-menopausal, surgically sterile or willing to use adequate contraception (barrier method with spermicide, intrauterine device (IUD), oral contraceptives, implant or other licensed hormone method) from time of study enrollment through 1 month after the last dose of study treatment.
• • Men must be surgically sterile or willing to use contraception (barrier method with spermicide) from time of study enrollment through 1 month after the last dose of study treatment.
• Exclusion Criteria:
• • Patients with herpes simplex virus (HSV) meningitis only, without evidence of HSV encephalitis.
• • Patients with an anticipated life expectancy \< 90 days.
• • Patients with creatinine clearance of less than or equal to 50ml/min./1.73 m\^2.
• • Pregnant or breastfeeding females.
• • Patients who have received any anti-herpesvirus medication (e.g. ganciclovir) other than intravenous acyclovir (ACV) for acute therapy of the current episode of herpes simplex encephalitis (HSE).
• • Patients who are unable to swallow oral medications at the time of study drug randomization (Day 0).
• • Patients who are \> 3 days beyond completion of treatment course with intravenous (IV) ACV.
• • Patients who are expected to receive long-term (\> 30 days/year) therapy with antiviral medications active against HSV \[e.g. ACV, valacyclovir (VACV), famciclovir\].